Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Revvity Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $92.99, while Revvity Inc trades at $116.17 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | RVTY | |
|---|---|---|
52-Week High | $97.99 | $117.75 |
52-Week Low | $92.76 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.075 with a modest 0.34% daily gain, though technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.31-$0.32 per share. Market sentiment is influenced by Treasury yield fluctuations and institutional positioning, with Bank of America increasing its stake by 69.8% in Q2 2026.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. Institutional accumulation provides support, but technical weakness and macroeconomic headwinds suggest limited near-term upside. Key risks include Fed rate policy uncertainty and oil price volatility affecting inflation expectations.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
